In 1995 Dr. Ehsan Hoque discovered that Lysophosphatidylcholine (LPC), a toxic substance which accumulates in the ischemic myocardium when applied exogenously, causes ischemia-like changes, suggesting that LPC is one of the important factors in producing ischemia-reperfusion derangements in terms of mechanical and metabolic functions.
In 1997 Dr. Ehsan Hoque was the first to demonstrate the potential protective effect of NHE (Na+-H+ Exchange) inhibition on Lysophosphatidylcholine (LPC) -induced cardiac injury [REF].